CIBA-GEIGY CATAFLAM LAUNCH PLANNED FOR LATE JANUARY
CIBA-GEIGY CATAFLAM LAUNCH PLANNED FOR LATE JANUARY following the Nov. 24 approval of the nonsteroidal anti-inflammatory drug, diclofenac potassium. Cataflam contains the same active ingredient as Voltaten (diclofenac sodium), which Ciba has marketed in the U.S. since 1988. Cataflam will be launched "toward the end of January," Ciba said. On Jan. 17, company reps will begin detailing the product to doctors, including primary care physicians, OB/GYNs, orthopedic surgeons and emergency room physicians.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth